On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 –– Assembled Cardiovascular Scientific Advisory Board (CV ...

In alignment with Jasper's clinical development plan, Jasper obtained regulatory clearance to enroll a 180mg dose cohort (n=12) in the SPOTLIGHT study, which is open and enrolling patients. Jasper ...

Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food ...

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable ...

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS ... Nasdaq Delisting and Subsequent ...

Pacs Group said it is conducting an internal audit and cooperating with a government investigation into its referral and ...

Former President Donald Trump has boasted in recent months about “Right To Try,” a law he signed in 2018. It’s aimed at ...